immunotherapy

Older adults aged 60 years and above accounted for almost 87 per cent of the diagnosed incident cases of bladder cancer in the 8MM…

Merck faces setback as Keytruda combination trials fail to expand cancer treatment ahead of patent loss

The International Agency for Research on Cancer (IARC) forecasts a 58 per cent surge in GI cancer cases by 2040 globally 

KEYTRUDA is now approved for 14 indications across eight tumour types in India

The technology enables the screening of substantial amounts of cancer samples without requiring fresh biopsies or biological…

Imfinzi is the only immunotherapy-based combination treatment option in India that offers significantly improved survival rates in…

In a clinical trial of 42 women with metastatic breast cancer, 28 (or 67 per cent) generated an immune reaction against their…

The four molecules expected to launch first, autogene cevumeran, GRANITE-001, ATL001, and Genocea Biosciences’ GEN-009 have…

Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined…

The designation will provide Glycostem with eligibility for seven years of market exclusivity and clear FDA guidance on specific…